Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: The Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

The Lancet Oncology

Volumn 11, Issue 5, 2010, Pages 459-464

  Ree, Anne Hansen ^a,b   Dueland, Svein ^a   Folkvord, Sigurd ^a   Hole, Knut H ^a   Seierstad, Therese ^a,c   Johansen, Marianne ^a   Abrahamsen, Torveig W ^a   Flatmark, Kjersti ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ACNE; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD CLOTTING DISORDER; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; ECG ABNORMALITY; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL CARCINOMA; HALLUCINATION; HOT FLUSH; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; MALE; NAUSEA; NEUTROPENIA; PELVIS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECTUM HEMORRHAGE; THROMBOCYTOPENIA; VAGINA BLEEDING; VOMITING; COLON TUMOR; GASTROINTESTINAL TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PELVIS TUMOR; RADIATION RESPONSE; RECTUM TUMOR; STOMACH TUMOR;

AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GASTROINTESTINAL NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PALLIATIVE CARE; PELVIC NEOPLASMS; RECTAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 77952310681     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70058-9     Document Type: Article

References (21)

1. Kastan MB, Bartek J Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
2. Ljungman M Targeting the DNA damage response in cancer. Chem Rev 2009, 109:2929-2950.
3. Tofilon PJ, Camphausen K Molecular targets for tumor radiosensitization. Chem Rev 2009, 109:2974-2988.
4. Zaidi SH, Huddart RA, Harrington KJ Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 2009, 6:103-134.
5. Bolden JE, Peart MJ, Johnstone RW Anti-cancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
6. Beamish H, Warrener R, Gabrielli BG Analysis of checkpoint responses to histone deacetylase inhibitors. Methods Mol Biol 2004, 281:245-259.
7. Munshi A, Tanaka T, Hobbs ML, et al. Vorinostat, a histone deacetylase inhibitor, enhances the reponse of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006, 5:1967-1974.
8. Camphausen K, Tofilon PJ Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007, 26:4051-4056.
9. Siegel D, Hussein M, Belani C, et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009, 2:31.
10. Flatmark K, Nome RV, Folkvord S, et al. Radiosensitization of colorectal carcinoma cells by histone deacetylase inhibition. Radiat Oncol 2006, 1:25.
11. Ree AH, Folkvord S, Flatmark K HDAC2 deficiency and histone acetylation. Nat Genet 2008, 40:812-813.
12. Folkvord S, Ree AH, Furre T, et al. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys 2009, 74:546-552.
13. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002, 360:307-308.
14. Lane AA, Chabner BA Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 32:5459-5468.
15. Di Gennaro E, Bruzzese F, Pepe S, et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or ralitrexed. Cancer Biol Ther 2009, 8:782-791.
16. Fazzone W, Wilson PM, Labonte MJ, et al. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 2009, 125:463-473.
17. Wilson PM, El-Khoueiry A, Iqbal S, et al. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 2010, 65:979-988.
18. Adjei AA, Christian M, Ivy P Novel design and end points for phase II clinical trials. Clin Cancer Res 2009, 15:1866-1872.
19. Hatfield P, Sebag-Montefiore D The use of radiotherapy in rectal cancer. Scand J Surg 2003, 92:65-73.
20. Prince HM, Bishton MJ, Harrison SJ Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15:3958-3969.
21. Marsoni S, Damia G, Camboni G A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 2008, 3:164-171.